MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease.
The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
|Mikhil N Bamne, PhD|
|Jude Jonassaint, RN|
160 United States sites
> 18 Years
Patients with sickle cell anemia
18 years old or older
African American healthy controls
18 years of age or older
Hemodialysis and active obstructive sleep apnea requiring treatment.
Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.